ArticleJournal of young pharmacists : JYP2013
Adverse drug reaction profile of anti-snake venom in a rural tertiary care teaching hospital.
Article in Journal of young pharmacists : JYP, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Rapid, label-free surface plasmon resonance discrimination between Bothrops and Crotalus venoms using clinical antivenom as the capture reagent.PLoS neglected tropical diseases · 2026Article
- Review
- Article
- A Nationwide Study on the Risks of Complications and Healthcare Costs of Snakebite Envenomation in Taiwan.The American journal of tropical medicine and hygiene · 2024Article
- A rare manifestation of serum sickness after common krait envenomation in a patient treated with polyvalent anti-snake venom in India: Presentation and challenges.Journal of family medicine and primary care · 2024Article
- Augmented rescue of macroglobulins by supplementation of anti-snake venom with methanolic extract of3 Biotech · 2022Article
- Bite-to-needle Time - An Extrapolative Indicator of Repercussion in Patients with Snakebite.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- Article
- Serious Adverse Reactions to Anti-snake Venom in Children with Snake Envenomation: An Underappreciated Contributor to Snakebite Mortality?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Article
- Evaluation of the merit of the methanolic extract of3 Biotech · 2021Article
- Health professionals' overestimation of knowledge on snakebite management, a threat to the survival of snakebite victims-A cross-sectional study in Ghana.PLoS neglected tropical diseases · 2021Article
- Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study.eLife · 2020Article
- Article
- Acute Severe Anaphylaxis in Nepali Patients with Neurotoxic Snakebite Envenoming Treated with the VINS Polyvalent Antivenom.Journal of tropical medicine · 2019Article
- Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise.British journal of haematology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe study was carried out with the aim of evaluation of the adverse drug reaction profile of anti-snake venom serum (ASV) in a rural tertiary care hospital.
methodsAn observational study was conducted in SRTR Medical College, Ambajogai, Maharashtra, India. A total number of 296 indoor case papers of snake bite from February to September 2011 and June to August 2012 were retrieved from the record section and the antivenom reactions were assessed. In addition, basic epidemiological data and prescribing practices of ASV were also analyzed.
resultsVasculotoxic snake bites were more common (50.61%) than neuroparalytic ones (22.56%). Mild envenomation was the commonest presentation. A total of 92 (56.10%) patients who received ASV suffered from antivenom reactions. The most common nature of reaction was chills, rigors (69.56%) followed by nausea and vomiting (34.8%). 10-15% patients suffered from moderate to severe reactions like hypotension and sudden respiratory arrest. We did not find any dose response relationship of ASV to risk of reactions (odds ratio 0.37). Intradermal sensitivity test was performed in about 72% cases.
conclusionOur study showed a higher incidence of reactions to ASV at our institute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.